首页> Blood advances> MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Manisha,Bhutani

第一单位： Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC.

作者： Manisha,Bhutani ^[1] ; Myra,Robinson ^[2] ; David,Foureau ^[3] ; Shebli,Atrash ^[1] ; Barry,Paul ^[1] ; Fei,Guo ^[3] ; Jason M,Grayson ^[4] ; Anna,Ivanina-Foureau ^[3] ; Mauricio,Pineda-Roman ^[1] ; Cindy,Varga ^[1] ; Reed,Friend ^[1] ; Christopher J,Ferreri ^[1] ; Xhevahire,Begic ^[5] ; Sarah,Norek ^[5] ; Tiffany,Drennan ^[5] ; Michelle B,Anderson ^[2] ; James T,Symanowski ^[2] ; Peter M,Voorhees ^[1] ; Saad Z,Usmani ^[6]

作者单位： Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC. ^[1] Department of Biostatistics and Data Sciences, Atrium Health Levine Cancer Institute, Charlotte, NC. ^[2] Department of Internal Medicine, Section of Hematology and Oncology, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC. ^[3] Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, NC. ^[4] Clinical Trials Office, Wake Forest Baptist Comprehensive Cancer Center, Atrium Health Levine Cancer, Charlotte, NC. ^[5] Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. ^[6]

医学主题词人类(Humans);多发性骨髓瘤(Multiple Myeloma);地塞米松(Dexamethasone);女(雌)性(Female);男(雄)性(Male);中年人(Middle Aged);肿瘤, 残余(Neoplasm, Residual);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);老年人(Aged);寡肽类(Oligopeptides);抗体, 单克隆(Antibodies, Monoclonal);成年人(Adult);治疗结果(Treatment Outcome)

DOI 10.1182/bloodadvances.2024014417

PMID 39576965

发布时间 2025-06-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood advances

2025年9卷3期

507-519页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Blood advances

2025年9卷3期

507-519页

检索历史清除

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

检索历史清除